

Structural and Mechanistic Studies of Mofegiline Inhibition of Recombinant Human Monoamine Oxidase B^{||}

Erika M. Milczek,[†] Daniele Bonivento,[‡] Claudia Binda,[‡] Andrea Mattevi,[‡] Ian A. McDonald,[§] and Dale E. Edmondson^{*,#}

Departments of Biochemistry and Chemistry, Emory University, 1510 Clifton Road, Atlanta, Georgia 30322, Department of Genetics and Microbiology, University of Pavia, Via Ferrata 1, Pavia, 27100 Italy, and Pharmaxis Ltd., Unit 2, 10 Rodborough Road, Frenchs Forest NSW 2086, Australia

Received September 19, 2008


Mechanistic and structural studies have been carried out to investigate the molecular basis for the irreversible inhibition of human MAO-B by mofegiline. Competitive inhibition with substrate shows an apparent K_i of 28 nM. Irreversible inhibition of MAO-B occurs with a 1:1 molar stoichiometry with no observable catalytic turnover. The absorption spectral properties of mofegiline inhibited MAO-B show features ($\lambda_{\max} \approx 450$ nm) unlike those of traditional flavin N(5) or C(4a) adducts. Visible and near-UV circular dichroism spectra of the mofegiline–MAO-B adduct shows a negative peak at 340 nm with an intensity similar to that of N(5) flavocyanine adducts. The X-ray crystal structure of the mofegiline–MAO-B adduct shows a covalent bond between the flavin cofactor N(5) with the distal allylamine carbon atom as well as the absence of the fluorine atom. A mechanism to explain these structural and spectral data is proposed.

Introduction

Monoamine oxidases (MAO^a) are flavin-dependent, outer mitochondrial membrane-bound enzymes that catalyze the oxidative deamination of amine neurotransmitters as well as dietary arylalkylamines (Scheme 1).¹ Reduction of O₂ to form H₂O₂ is concomitant with oxidation of the reduced cofactor. Mammals (including humans) contain the MAO-A and MAO-B isozymes that are separate gene products and exhibit differing substrate and inhibitor specificities.^{2,3} The isozymes share ~70% sequence identity and are differentially expressed in various tissues and in different amounts as a function of age.⁴ There is an increasing level of evidence supporting the suggestion that increased levels of MAO-B in neuronal tissue on aging in humans⁵ is related to the onset of neurodegenerative diseases such as Parkinson's or Alzheimer's diseases. Current treatment invoking MAO-B specific inhibitors in combination with levodopa has been shown to improve motor fluctuations in patients with Parkinson's disease.^{6,7} Therefore, continued investigations of MAO-B specific inhibitors as neuroprotectants is important.

Mofegiline (Figure 1) is a mechanism-based inhibitor developed by the Merrell-Dow Research Institute in the 1980s for the treatment of Parkinson's disease.^{8,9} This compound demonstrated nanomolar inhibitory properties for the inhibition of rat brain mitochondrial MAO-B and was shown to be highly specific for rat MAO-B with a 190-fold higher affinity for the MAO-B isoform. Additional pharmacological interest in mofegiline stems from its anti-inflammatory properties via the inactivation of the copper-dependent amine oxidase, semicar-

Scheme 1. Reaction Pathway for the Oxidation of Amines Catalyzed by MAO²¹



bazide-sensitive amine oxidase (SSAO/VAP-1).¹⁰ While information on the potency of mofegiline has been known for some time, the molecular mechanism of inhibition as well as the molecular basis for its high level of specificity remains unknown.

It was proposed that this compound acts as a mechanism-based inhibitor of MAO-B in line with the earlier observations by Rando and Eigner¹¹ who demonstrated that chloroallylamine was a time-dependent, irreversible inhibitor of MAO. Their studies suggested that inhibition of rat liver MAO by allylamine occurs via oxidation of the amine moiety followed by covalent adduct formation with the N(5) position of the flavin. This proposal was supported by the observation that the absorption spectrum of the enzyme-bound flavin is "bleached" after inhibition and remains in this form after removal of excess reagent either by gel filtration or by dialysis (Scheme 2A). This suggestion was later challenged by Silverman and co-workers¹² when they showed that tritium labeled allylamine remains attached to the protein after denaturation and demonstrated that the flavin is reoxidized on denaturation. These observations led to the proposal that inhibition is achieved by catalytic oxidation of allylamine to its imine followed by Michael addition of an




Figure 1. Structure of mofegiline.

^{||} Atomic coordinates have been deposited in the Protein Data Base with code 2vz2.

* To whom correspondence should be addressed. Phone: +01-404-727-5972. Fax: +01-404-727-2738. E-mail: deedmon@emory.edu.

[†] Department of Chemistry, Emory University.


[‡] University of Pavia.

[§] Pharmaxis Ltd.

[#] Department of Biochemistry, Emory University.

^a Abbreviations: MAO, monoamine oxidase; SSAO, semicarbazide-sensitive amine oxidase; TISAB, total ion strength adjustment buffer; ADA, *N*-(2-acetamido)iminodiacetic acid; PEG 4000, polyethylene glycol 4000; CD, circular dichroism.

Scheme 2. (A) Proposed Mechanism for Allylamine Inhibition of MAO Proposed by Rando and Eigner¹¹ and (B) Proposed Mechanism of Allylamine Inhibition of MAO Proposed by Silverman¹²



active site nucleophilic amino acid residue to the unsaturated imine (Scheme 2B). This proposed mechanism has prevailed in subsequent discussions describing the mode of MAO inhibition of allylamine inhibitor analogues, like mofegiline, during the past 20 years.^{8,13,14} To our knowledge, no studies on the molecular level have been published on the inhibition of human MAO-A or -B with allylamine analogues. All previous studies have utilized either bovine or rat mitochondrial MAO.^{11,12}

With access to purified recombinant human MAO-A¹⁵ and MAO-B¹⁶ as well as conditions for the crystallization of inhibitor-bound MAO-B,¹⁷ we initiated a collaborative study to further define the molecular details for the inhibition of human MAO-B with mofegiline. A combination of solution and crystallographic studies demonstrates that mofegiline inhibits human MAO-B via covalent flavin modification in a rapid and highly specific reaction.

Results

Inhibition of Human MAO-B with Mofegiline. Incubation of purified human MAO-B with mofegiline leads to rapid and irreversible stoichiometric inhibition of catalytic activity. Reversible binding of mofegiline to the catalytic site of MAO-B prior to irreversible inactivation is shown from competitive inhibition experiments which show an apparent K_i of 28 nM (see Supporting Information), a value close to the IC_{50} value (3.6 nM) determined for membrane bound rat MAO-B.⁸ The data in Figure 2 show a linear loss of activity on titration of MAO-B with substoichiometric amounts of mofegiline with complete inhibition observed at a stoichiometry of 1.0 mol of mofegiline/mol of E-FAD. Inhibition occurs rapidly and is complete by the time an enzyme sample can be withdrawn and assayed. Titration of enzyme samples with inactive protein in solution results in lower stoichiometries for complete inhibition, demonstrating the requirement for functional enzyme involvement in the reaction. Ion-selective electrode experiments show the release of 1 mol of fluoride ion/mol of MAO-B inhibited which confirms that fluoride is eliminated during the inhibition reaction. When the visible absorption spectrum of the enzyme (due to the covalent FAD) is monitored during the titration, spectral perturbations are observed (Figure 3); however, no "bleaching" of the oxidized flavin absorbance at 455 nm is observed, as expected if either flavin N(5) or C(4a) adducts were formed. For comparison, the spectral data in Figure 4 show spectral changes observed for phenethylhydrazine-inhibited

MAO-B (N(5) adduct)¹⁸ and for tranylcypromine-inhibited MAO-B (C(4a) adduct).¹⁷ The flavin absorbance shifts in λ_{max} from 455 to 445 nm on mofegiline inhibition of MAO-B along with a small increase in the molar extinction coefficient from $12\,000\text{ M}^{-1}\cdot\text{cm}^{-1}$ to $12\,900\text{ M}^{-1}\cdot\text{cm}^{-1}$ (Figure 3). Difference spectral data (inset, Figure 3) show that maximal spectral changes on inhibition occur in the near-UV region with a minimum at 370 nm, a maximum at 320 nm, and isosbestic points at 350 and 395 nm.

These spectral data suggest that the inhibitor binds in the vicinity of the covalent FAD but do not suggest a covalent modification of the coenzyme. If that scenario were true, the FAD cofactor should be reactive to chemical reduction by sodium dithionite. The addition of excess dithionite to a sample of mofegiline-inhibited MAO-B shows no reduction of the flavin by the criteria that no observable bleaching in the 455 nm absorption of the flavin ring occurs. When dithionite is added to a sample of mofegiline-inhibited MAO-B complex in the presence of nonfunctional enzyme, only a partial bleaching of the 455 nm absorption occurs (data not shown). These experiments show that the flavin coenzyme in mofegiline-inhibited MAO-B is resistant to chemical reduction and that nonfunctional




Figure 2. Effect of substoichiometric levels of mofegiline on the activity of human MAO-B. The titration was carried out in 50 mM potassium phosphate, pH 7.5, and 0.8% (w/v) β -D-octylglucoside.




Figure 3. Effect of mofegiline inhibition of MAO-B on the absorption spectra in the visible and near-UV region due to the flavin: (black curve) 0.0, (red curve) 0.2, (green curve) 0.4, (purple curve) 0.6, (blue curve) 0.8, (pink curve) 1.0 (mol mofegiline/mol MAO-B). Inset shows the difference absorption spectra observed on subtraction of the spectrum of uninhibited MAO-B from those observed during the titration: (black curve) 0.0, (red curve) 0.2, (green curve) 0.4, (purple curve) 0.6, (blue curve) 0.8, (pink curve) 1.0 (mol mofegiline/mol MAO-B).

MAO-B is unreactive with mofegiline, which further supports the conclusion that this compound is a mechanism-based inhibitor. The visible CD spectrum of the mofegiline–MAO-B complex (Figure 5) differs from that of free enzyme with an intense negative dichroic band at 340 nm which is similar in both position and intensity to those CD spectra of MAO-B inhibited by compounds forming covalent flavin N(5) adducts (Figure 5).

To determine whether catalytic turnover is involved in the inhibition reaction, the influence of oxygen in the inhibition process was examined. Inhibition reactions carried out in the presence of a coupled enzyme system that detects whether any H_2O_2 is produced (Amplex Red/Horseradish Peroxidase)¹⁹ show no detectable levels of H_2O_2 . The addition of mofegiline to oxidized MAO-B under anaerobic conditions results in complete inhibition of the enzyme with spectral properties (Figure 6) identical to that of found during aerobic inhibition of the enzyme. Assays of anaerobically withdrawn samples show complete inhibition. No spectral changes are detected on exposure of anaerobic mofegiline-inhibited MAO-B to air. These experiments demonstrate that no catalytic turnover occurs during the inhibition. If mofegiline is a mechanism-based inhibitor, inhibition occurs during a single turnover.

To probe whether reduced MAO-B is subject to inhibition by mofegiline, a sample of enzyme was reduced anaerobically with a stoichiometric amount of benzylamine. Mofegiline was then anaerobically added and the visible absorbance spectral properties of the enzyme followed. The data in Figure 7 show that the absorbance of the reduced enzyme increases on addition of mofegiline to level only ~50% of that observed with mofegiline-inhibited MAO-B formed under aerobic conditions. The anaerobic removal and assay of an aliquot of enzyme from this experiment exhibit no activity. Upon exposure to oxygen, the spectrum exhibits properties identical to those of aerobically inhibited MAO-B. Attempts to determine the rate of MAO-B flavin reduction by mofegiline by stopped flow experiments show that the rate is too fast to measure and occurs within the 1–2 ms dead time of the instrument.




Figure 4. Visible and near-UV absorption spectra of flavin N(5) and of flavin C(4a) adducts of MAO-B: (A) oxidized MAO-B (---) and after phenylethylhydrazine inhibition (N(5) flavin adduct) (—); (B) oxidized MAO-B (---) and after tranylcypromine inhibition (C(4a) adduct) (—).

Structure of Mofegiline-Inhibited MAO-B. To provide conclusive evidence for suggested covalent modification of MAO-B on inhibition by mofegiline, the inhibited enzyme was crystallized and its structure determined by X-ray crystallography. Crystals of mofegiline-inhibited MAO-B diffract to 2.3 Å resolution. The structure of the complex about the flavin active site is shown in Figure 8. These structural data provide direct evidence that the inhibitor is bound to the enzyme as a flavin N(5) adduct (Figure 8). The inhibitor adopts an extended conformation spanning from the flavin ring to the entrance of the substrate cavity. The aromatic ring is located in the rear of the cavity, and it is oriented perpendicular to the flavin ring as typically observed for most other MAO-B–inhibitor complexes.¹⁷ Ile199 adopts a conformation in which its side chain is positioned in the “open” conformation resulting in the fusion of the entrance and substrate cavities. This “open” conformation has been previously observed with other bulky inhibitors such as *N*-(2-aminoethyl)-4-chlorobenzamide and 1,4-diphenyl-2-butene, which also force the opening of the Ile199 gate.¹⁷ The bound mofegiline participates in numerous hydrophobic and van der Waals interactions with active site side chains (Cys172, Ile198, Ile199, Phe343, Tyr326, Tyr398, and Tyr 435). The electron density clearly defines the positions of several ordered water molecules, one of which forms an H-bond interaction with the mofegiline nitrogen atom. No extra electron density is found close to the covalent bond of the flavin N(5), which proves that




Figure 5. Circular dichroism spectra of oxidized human MAO-B, mofegiline inhibited MAO-B, and known MAO-B flavin N(5) adducts: oxidized MAO-B (black curve); after inhibition by mofegiline (red curve); the MAO-B–N(5) flavin adduct formed after inhibition by pargyline (green curve); the MAO-B–N(5) flavin adduct formed after inhibition by phenylethylhydrazine (purple curve). All spectral data were acquired in 50 mM potassium phosphate, pH 7.5, containing 0.8% (w/v) β -D-octylglucoside.




Figure 6. Visible and near-UV absorption spectra observed after anaerobic inhibition of MAO-B by mofegiline: oxidized MAO-B (black curve); mofegiline–MAO-B adduct under argon (red curve); mofegiline–MAO-B adduct formed aerobically (purple curve). The buffer used is 50 mM potassium phosphate, pH 7.5, and 0.8% (w/v) β -D-octylglucoside.

the fluorine atom has been eliminated and supports the argument that the carbon (from mofegiline) is sp^2 hybridized. The mofegiline nitrogen atom, which we interpret as an imine group, lies in front of the flavin ring between side chains of Tyr398 and Tyr435 that form the catalytically important aromatic cage²⁰ (Figure 8B). These structural data support the idea that the aromatic cage can function as a recognition site for the substrate amine group.²¹

Mofegiline Interactions with Purified Human MAO-A. A similar series of experiments were performed using recombinant human MAO-A to compare inhibition properties that might help explain why mofegiline exhibits a marked specificity for MAO-B. Mofegiline functions as a competitive inhibitor with MAO-A




Figure 7. Absorption spectral changes in MAO-B after anaerobic reduction with a stoichiometric amount of benzylamine followed by the anaerobic addition of 1.5 mol equiv of mofegiline. Exposure of the sample to oxygen results in additional spectral changes in the flavin absorption region to a spectrum that is identical to that observed with aerobically inhibited MAO-B with mofegiline. Absorption spectra are as follows: oxidized MAO-B (black curve); reduced MAO-B (red curve); after the anaerobic addition of mofegiline (purple curve); sample after exposure to air (blue curve). The buffer used is 50 mM potassium phosphate, pH 7.5, and 0.8% (w/v) β -D-octylglucoside.

with a measured K_i value ($1.1 \mu\text{M}$) ~ 40 -fold weaker than that observed with MAO-B. Dilution of the MAO-A–inhibitor mixture shows return of catalytic activity, demonstrating that no irreversible inhibition occurs. Like MAO-B, inhibition reactions carried out in the presence of the Amplex red/horseradish peroxidase coupled assay show no detectable levels of H_2O_2 produced; therefore, no catalytic oxidation of the amine moiety is observed for MAO-A. Similarly, the anaerobic addition of mofegiline to MAO-A shows no evidence for enzyme flavin reduction even at high concentrations of inhibitor (Figure 9). These experiments suggest that the failure of MAO-A to oxidize the amine moiety of mofegiline may account for its resistance to inhibition.

Anaerobic substrate reduction of MAO-A followed by the addition of mofegiline does not result in any irreversible inhibition but does show modest spectral changes from 300 to 350 nm in the UV/visible spectrum (Figure 10). The CD spectrum of the mofegiline–MAO-A complex exhibits a mild perturbation of the flavin spectrum; however, the spectrum does not resemble those of MAO-A–flavin N(5) adducts (data not shown). These experiments demonstrate mofegiline is a weaker, reversible MAO-A inhibitor that is much more potent for MAO-B. The structural basis for this difference in behavior of mofegiline for the two isozymes will be addressed in the Discussion.

Discussion

Model system studies have shown that reduced flavins are known to react with alkyl halides to form flavin N(5) adducts.²² Recent studies of the flavin dependent isopentenyl pyrophosphate isomerase²³ have shown that fluorinated substrate analogues react with the reduced flavin coenzyme to form flavin N(5) alkyl adducts with elimination of the fluorine atom as F^- . With the knowledge of the behavior of these flavin alkylating systems, we suggest that the initial step of the inhibition of MAO-B by mofegiline involves flavin reduction concurrent with




Figure 8. Structure of human MAO-B in complex with the mofegiline: (A) stereoview of the final $2F_o - F_c$ electron density map (contoured at the 1.3σ level); (B) binding mode of mofegiline to the human MAO-B active site. Carbons are in black, oxygen in red, nitrogen in blue, sulfurs in yellow, and fluorine in gray. In part B, the inhibitor covalent bonds are depicted in gray. The H-bond between the inhibitor nitrogen atom and a water molecule is outlined by a dashed line. With respect to part A, the model has been rotated by about 60° around the vertical axis in the plane of the paper. The drawings were produced by using Bobscrip³⁴ and Molscrip.³⁵

amine oxidation to the imine **1**. The imine intermediate **1** then undergoes a Michael addition of the sp^3 N(5) of the flavin hydroquinone. The instability of the enamine intermediate **2** results in elimination of F^- to form the highly conjugated flavin N(5) adduct **3** (Scheme 3). This inhibition reaction is very rapid and occurs in a single catalytic turnover, since no O_2 uptake or H_2O_2 production is observed during inhibition.

Preliminary interpretations of the UV/vis profile of the mofegiline–MAO-B complex suggest that the flavin absorption bands are perturbed on mofegiline inhibition but that no covalent addition to the flavin moiety occurs. However, the X-ray crystal structure of the mofegiline–MAO-B complex and the supporting CD data demonstrate that the flavin is indeed modified on mofegiline inhibition but in a manner with both differences and similarities with flavin adducts involving alkylation at N(5) or C(4a). The data collected from the reaction of reduced MAO-B with mofegiline (Figure 7) show that the initial adduct, while inactive, is not identical with the mofegiline adduct formed on aerobic inhibition. The incomplete spectral changes may be

indicative of flavin reoxidation by reduction of the vinyl group of mofegiline. The reduction of olefins by flavin containing enzymes has long been known.^{24,25} The observed increase in the absorption spectrum upon exposure to oxygen reflects full oxidation of the enzyme followed by mofegiline–adduct formation signaling the requirement for amine reduction to attain mofegiline–MAO-B adduct formation. These data provide additional support for the hypothesis that mofegiline inhibits MAO-B by initially reducing the flavin.

One interesting aspect that deserves further study is the description of factors that give the N(5) alkylated flavin its absorption spectral properties that differ marginally from those of the oxidized form of the flavin and differ extensively from those exhibited by other N(5) or C(4a) flavin adducts. The most reasonable explanation is that the extensive conjugation of the N(5) alkyl group (including the vinyl double bond and the imine double bond) with the flavin ring is sufficient to permit the spectral transitions found in the 450 nm region. Addition of acetylenic inhibitors to the MAO-B or MAO-A flavins result




Figure 9. Spectral changes in the UV/visible spectrum of human MAO-A on anaerobic addition of a 10-fold molar excess of mofegiline. Only small spectral changes in the flavin chromophore occur after incubation times of greater than 30 min. Absorption spectra are as follows: oxidized MAO-A (black curve); after the anaerobic addition of mofegiline (red curve); mofegiline and MAO-A incubated aerobically at 25 °C for 30 min (purple curve).





Figure 10. Absorption spectral changes on the anaerobic reduction of MAO-A with a stoichiometric amount of *p*-trifluoromethylbenzylamine followed by the anaerobic addition of 10-fold excess mofegiline (which does not result in any observed spectral changes). Exposure of the sample to oxygen shows reoxidation of the flavin with minor changes in the 300–350 nm region of the spectrum. Absorption spectra are as follows: oxidized MAO-B (black curve); reduced MAO-B (red curve); after the anaerobic addition of mofegiline (green curve); after exposure of the sample to O₂ (blue curve). The buffer used is 50 mM potassium phosphate, pH 7.5, and 0.8% (w/v) β -D-octylglucoside.

in N(5) flavocyanine adducts with maximal absorption at 415 nm and an ϵ_M of 21 000 M⁻¹·cm⁻¹ reflecting their extended conjugation.²⁶ Geometric differences between these two types of MAO-B flavin N(5) adducts likely contribute to their observed spectral differences (Figure 11).

Unlike MAO-B, mofegiline is a reversible competitive inhibitor of MAO-A and does not form a covalent adduct with the flavin. Addition of high concentrations of mofegiline to MAO-A results in only modest spectral changes in the 300–400 nm region of the flavin UV/vis spectrum and no reduction of

Scheme 3. Proposed Mechanism for the Irreversible Inhibition of MAO-B by Mofegiline with N(5) Flavin Alkylation to Produce a Highly Conjugated Flavocyanine Adduct



the flavin upon extended incubation (Figure 9). The CD spectral data do not support the formation of a flavin-N(5) adduct with MAO-A. An explanation for this differential behavior between MAO-A and MAO-B is found on comparison of their respective substrate specificities. Previous and current data show that




Figure 11. Comparison of absorption spectral properties of MAO-B and the flavin adducts of MAO-B adducts with various inhibitors: oxidized MAO-B (black curve); pargyline-inhibited MAO-B (red curve); phenylethylhydrazine-inhibited MAO-B (green curve); mofegiline-inhibited MAO-B (purple curve).

4-phenylbutylamine is a competitive inhibitor of human MAO-A ($K_i = 31 \mu\text{M}$)²⁷ but is a substrate for human MAO-B ($k_{\text{cat}} = 109 \pm 5 \text{ min}^{-1}$ and $K_m = 19 \pm 3 \mu\text{M}$; $k_{\text{cat}}/K_m = 5.8 \text{ min}^{-1} \cdot \mu\text{M}^{-1}$). Mofegiline is a close structural analogue of 4-phenylbutylamine and thus is poorly suited to function as a substrate for MAO-A but does so for MAO-B. These considerations further support the notion that amine oxidation is a requirement for irreversible inhibition of MAO-B by mofegiline. The Michael addition of nucleophiles to a conjugated Michael acceptor occurs much more rapidly than addition to an unconjugated vinyl group, supporting the requirement for amine oxidation to an imine for inactivation to occur. In addition, steric factors are likely involved in the nonreactivity of the amine moiety of mofegiline for MAO-A. However, prereducing the flavin of MAO-A with a stoichiometric amount of substrate does not influence its reactivity toward mofegiline (Figure 10).

Conclusions

Mofegiline is a highly selective, stoichiometric inhibitor of MAO-B that forms an N(5) adduct with the covalent flavin coenzyme in a single catalytic turnover. X-ray structural data of the inhibited enzyme provide definitive evidence for the structure of the inhibited form. The conjugated iminium group is the site for nucleophilic attack by the N(5) of the reduced flavin, which is followed by irreversible fluoride elimination. The resulting N(5) adduct is highly conjugated with spectral properties more like those of resting oxidized flavin or to N(5) flavocyanine adducts than to other N(5) or C(4a) alkyl flavins. The high level of mofegiline selectivity toward MAO-B is suggested to result from the nature of its alkyl side chain, which is a feature that should be taken into consideration for the design of future MAO-A or MAO-B specific inhibitors.

Materials and Methods

Recombinant human liver MAO-B and MAO-A were expressed in *Pichia pastoris* and purified as described previously.^{15,16} Mofegiline was synthesized according to a published procedure.^{28,29} Standard MAO-A and MAO-B assays were performed spectrophotometrically using kynuramine and benzylamine, respectively, at 25 °C in a 50 mM phosphate buffer (pH 7.5) and 0.5% (w/v) RTX-100.

Competitive Inhibition Assays. K_i values for mofegiline inhibition of MAO-A and MAO-B were determined by measuring the initial rates of substrate oxidation (six different concentrations) in the presence of varying concentrations of inhibitor (four different concentrations). All samples were incubated for 5 min at 25 °C prior to the addition of enzyme. K_i values were calculated by plotting the apparent K_m values for each mofegiline concentration as a function of mofegiline concentration.

Fluoride Electrode Experiment. A sample of human MAO-B (10 μM , 10 nmol) was desalted by gel filtration over a G-25 Sephadex column in 50 mM potassium phosphate buffer (pH 7.5), 0.8% *n*-octyl- β -D-glucopyranoside, and 20% glycerol. The enzyme sample was inhibited with 1 equiv of mofegiline (2.3 μg , 10 nmol), immediately filtered over a PM-10 filter, and subsequently adjusted with total ion strength adjustment buffer (TISAB III with CDTA) to balance the ion concentration. The filtrate was analyzed by an Accumet combination fluoride specific electrode. The released fluoride concentration was verified by the addition of an internal fluoride standard. A control sample of human MAO-B in the absence of mofegiline was prepared by following the same experimental protocol.

Circular Dichroism Spectroscopy. An Aviv model 62DS circular dichroism spectrophotometer was utilized for the collection of the spectra reported. All spectra were collected from 550 to 300 nm with a 1 s dwell time in a 1 cm path length cell. Samples were analyzed in 3 mL quartz cells with concentrations ranging from 25 to 40 μM . A total of five repetitive scans were averaged, and the spectra were smoothed using an adjacent-point averaging function.

Table 1. Data Collection and Refinement Statistics

	MAO-B–mofegiline complex
space group	C222
unit cell (Å)	$a = 132.0$; $b = 223.7$; $c = 86.6$
resolution (Å)	2.3
$R_{\text{sym}}^{a,b}$ (%)	11.2 (34.4)
completeness ^b (%)	97.7 (99.9)
unique reflections	55 954
Redundancy	4.0 (4.0)
$I/\sigma^{b,c}$	12.0 (3.2)
average B for ligand atoms (Å ²)	32.2
R_{cryst}^d (%)	18.7
R_{free}^d (%)	22.9
rms bond length (Å)	0.008
rms bond angles (deg)	1.09

^a $R_{\text{sym}} = \sum |I_i - \langle I \rangle| / \sum I_i$, where I_i is the intensity of i th observation and $\langle I \rangle$ is the mean intensity of the reflection. ^b Values in parentheses are for reflections in the highest resolution shell. ^c The final model consists of residues 3–501 of MAO-B chain A, residues 3–496 of MAO-B chain B, two FAD–mofegiline adducts, two molecules of Zwittergent 3-12, and 416 water molecules. ^d $R_{\text{cryst}} = \sum |F_{\text{obs}} - F_{\text{calc}}| / \sum |F_{\text{obs}}|$ where F_{obs} and F_{calc} are the observed and calculated structure factor amplitudes, respectively. The set of reflections used for R_{free} calculations and excluded from refinement was extracted from the structure factor file relative to the PDB entry 2vz2.

Crystallographic Methods. Crystallographic studies were performed as described.¹⁷ Briefly, inhibited human MAO-B in 50 mM potassium phosphate, pH 7.5, 8.5 mM Zwittergent 3-12 was crystallized by mixing equal volumes of protein sample and reservoir solution (12% PEG4000, 100 mM ADA buffer, pH 6.5, 70 mM Li_2SO_4). X-ray diffraction data were collected at 100 K at the beam-line ID14-EH2 of European Synchrotron Radiation Facility in Grenoble, France. Data processing and scaling were carried out using MOSFLM³⁰ and programs of the CCP4 package.³¹ The coordinates of the MAO-B–isatin complex¹⁷ were used as initial model after removal of all water and inhibitor atoms. Crystallographic refinements were performed with the programs REFMAC5³² and Coot.³³ Refinement statistics are listed in Table 1.

Acknowledgment. This work was supported by National Institutes of Health Grant GM-29433 and National Institute of Neurological Disorders and Stroke Award No. F31NS063648 (to E.M.M.). We are grateful to Milagros Aldeco and to Dr. Jin Wang for their helpful discussions and valuable technical assistance throughout this project.

Supporting Information Available: Competitive inhibition data for mofegiline inhibition of human MAO-B and human MAO-A. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- (1) Shih, J. C.; Chen, K.; Ridd, M. J. Monoamine oxidase: from genes to behavior. *Annu. Rev. Neurosci.* **1999**, *22*, 197–217.
- (2) Weyler, W.; Hsu, Y. P.; Breakefield, X. O. Biochemistry and genetics of monoamine oxidase. *Pharmacol. Ther.* **1990**, *47*, 391–417.
- (3) Rodriguez, M. J.; Saura, J.; Billett, E. E.; Finch, C. C.; Mahy, N. Cellular localization of monoamine oxidase A and B in human tissues outside of the central nervous system. *Cell Tissue Res.* **2001**, *304*, 215–220.
- (4) Bach, A. W.; Lan, N. C.; Johnson, D. L.; Abell, C. W.; Bembek, M. E.; et al. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. *Proc. Natl. Acad. Sci. U.S.A.* **1988**, *85*, 4934–4938.
- (5) Fowler, J. S.; Volkow, N. D.; Wang, G. J.; Logan, J.; Pappas, N.; et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. *Neurobiol. Aging* **1997**, *18*, 431–435.
- (6) Olanow, C. W. Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. *Neurology* **2006**, *66*, S69–S79.
- (7) Rascol, O.; Brooks, D. J.; Melamed, E.; Oertel, W.; Poewe, W.; et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. *Lancet* **2005**, *365*, 947–954.

- (8) Palfreyman, M. G.; McDonald, I. A.; Zreika, M.; Cremer, G.; Haegel, K. D.; et al. MDL-72,974a, a selective MAO-B inhibitor with potential for treatment of Parkinson's disease. *J. Neural Transm., Suppl.* **1993**, *40*, 101–111.
- (9) McDonald, I. A.; Lacoste, J. M.; Bey, P.; Palfreyman, M. G.; Zreika, M. Enzyme-activated irreversible inhibitors of monoamine-oxidase—phenylallylamine structure activity relationships. *J. Med. Chem.* **1985**, *28*, 186–193.
- (10) Palfreyman, M. G.; McDonald, I. A.; Bey, P.; Danzin, C.; Zreika, M.; et al. Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential. *J. Neural Transm., Suppl.* **1994**, *41*, 407–414.
- (11) Rando, R. R.; Eigner, A. Pseudo-irreversible inhibition of monoamine-oxidase by allylamine. *Mol. Pharmacol.* **1977**, *13*, 1005–1013.
- (12) Silverman, R. B.; Hiebert, C. K.; Vazquez, M. L. Inactivation of monoamine oxidase by allylamine does not result in flavin attachment. *J. Biol. Chem.* **1985**, *260*, 14648–14652.
- (13) Palfreyman, M. G.; McDonald, I. A.; Bey, P.; Schechter, P. J.; Sjoerdsma, A. Design and early clinical evaluation of selective inhibitors of monoamine oxidase. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **1988**, *12*, 967–987.
- (14) McDonald, I. A.; Lacoste, J. M.; Bey, P.; Wagner, J.; Zreika, M.; et al. Dual enzyme-activated irreversible inhibition of monoamine-oxidase. *Bioorg. Chem.* **1986**, *14*, 103–118.
- (15) Li, M.; Hubalek, F.; Newton-Vinson, P.; Edmondson, D. E. High-level expression of human liver monoamine oxidase A in *Pichia pastoris*: comparison with the enzyme expressed in *Saccharomyces cerevisiae*. *Protein Expression Purif.* **2002**, *24*, 152–162.
- (16) Newton-Vinson, P.; Hubalek, F.; Edmondson, D. E. High-level expression of human liver monoamine oxidase B in *Pichia pastoris*. *Protein Expression Purif.* **2000**, *20*, 334–345.
- (17) Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D. E.; et al. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 9750–9755.
- (18) Binda, C.; Wang, J.; Li, M.; Hubalek, F.; Mattevi, A.; et al. Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B. *Biochemistry* **2008**, *47*, 5616–5625.
- (19) Zhou, M.; Panchuk-Voloshina, N. A one-step fluorometric method for the continuous measurement of monoamine oxidase activity. *Anal. Biochem.* **1997**, *253*, 169–174.
- (20) Li, M.; Binda, C.; Mattevi, A.; Edmondson, D. E. Functional role of the “aromatic cage” in human monoamine oxidase B: structures and catalytic properties of Tyr435 mutant proteins. *Biochemistry* **2006**, *45*, 4775–4784.
- (21) Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D. E.; Mattevi, A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. *Nat. Struct. Biol.* **2002**, *9*, 22–26.
- (22) Müller, F.; Hemmerich, P.; Ehrenber, A.; Palmer, G.; Massey, V. Chemical and electronic structure of neutral flavin radical as revealed by electron spin resonance spectroscopy of chemically and isotopically substituted derivatives. *Eur. J. Biochem.* **1970**, *14*, 185.
- (23) Rothman, S. C.; Johnston, J. B.; Lee, S.; Walker, J. R.; Poulter, C. D. Type II isopentenyl diphosphate isomerase: irreversible inactivation by covalent modification of flavin. *J. Am. Chem. Soc.* **2008**, *130*, 4906–4913.
- (24) Benson, T. E.; Marquardt, J. L.; Marquardt, A. C.; Eitzkorn, F. A.; Walsh, C. T. Overexpression, purification, and mechanistic study of Udp-N-acetylenolpyruvylglucosamine reductase. *Biochemistry* **1993**, *32*, 2024–2030.
- (25) Benson, T. E.; Walsh, C. T.; Massey, V. Kinetic characterization of wild-type and S229A mutant MurB: evidence for the role of ser 229 as a general acid. *Biochemistry* **1997**, *36*, 796–805.
- (26) Hubalek, F.; Binda, C.; Li, M.; Herzig, Y.; Sterling, J.; et al. Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. *J. Med. Chem.* **2004**, *47*, 1760–1766.
- (27) Nandigama, R. K.; Edmondson, D. E. Structure–activity relations in the oxidation of phenethylamine analogues by recombinant human liver monoamine oxidase A. *Biochemistry* **2000**, *39*, 15258–15265.
- (28) Evans, J. C.; Goralski, C. T.; Rand, C. L.; Vosejka, P. C. Process for the Preparation of (E)-1-Amino-2-(fluoromethylene)-4-(p-fluorophenyl)butane, Novel Processes for Preparing an Intermediate Thereof, And Novel Intermediates Thereof. U.S. Patent 5488188, 1996; 9 pp. (Merrell Dow Pharmaceuticals Inc.).
- (29) McDonald, I. A.; Bey, P.; Zreika, M.; Palfreyman, M. G. MDL 72,974A monoamine oxidase type B inhibitor. *Drugs Future* **1991**, *16*, 428–431.
- (30) Leslie, A. G. W. Integration of macromolecular diffraction data. *Acta Crystallogr., Sect. D* **1999**, *55*, 1696–1702.
- (31) Bailey, S. The Ccp4 Suite. Programs for Protein Crystallography. *Acta Crystallogr., Sect. D* **1994**, *50*, 760–763.
- (32) Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr., Sect. D* **1997**, *53*, 240–255.
- (33) Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics. *Acta Crystallogr., Sect. D* **2004**, *60*, 2126–2132.
- (34) Esnouf, R. M. Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. *Acta Crystallogr., Sect. D* **1999**, *55*, 938–940.
- (35) Kraulis, P. J. Molscript, a program to produce both detailed and schematic plots of protein structures. *J. Appl. Crystallogr.* **1991**, *24*, 946–950.

JM8011867